1

Partnerships That Accelerate Innovation:1+1=11

June 12, 2013

2

Presentation Overview The Issues New Opportunities for Collaboration How Massachusetts is Supporting New

Opportunities for Collaboration

3

The Issues – A Brief Summary Drug pipelines are running dry and many “blockbuster

medicines” are about to lose patent protection Traditional drug-development processes at big pharma are

expensive and inefficient; the traditional business model at big pharma also is expensive and inefficient

Acquisition of biotech firms by big pharma is not solving the problem

Solutions to some of the most pressing problems lie at the intersection of diagnostiscs, biopharma, medical technology (devices), and computing

Collaboration is an increasingly important solution!

4

The Issues New Opportunities for Collaboration How Massachusetts is Supporting New

Opportunities for Collaboration

5

Public-Private Partnerships

Collaborations that are:

Focused on shared challenges that are critical for progress…

…and are increasingly difficult for a single sector to tackle, and/or finance alone…

…where solutions can benefit both the public and private sector (and the broader economy)

6

Pre-competitive Consortia

Collaborations that are:

Focused on shared challenges that are critical for progress…

…and are increasingly difficult for a single organization to tackle alone…

…but cannot be exploited as a standalone profit-making opportunity for any individual participant

7

Models of Pre-competitive Consortia*1. Open source initiatives

2. Industry consortia for R&D process innovation

3. Discovery-enabling consortia

4. Public-private consortia for knowledge creation

5. Prizes

6. Innovation incubators/insourcing

7. Industry complementor relationships

8. Virtual pharma companies

*Altschulergray (2010)

Who Accesses OutputsW

ho P

artic

ipat

es/C

ontr

ibut

esOpen Restricted

Open

Restricted

8

International Collaboration

In mature industry sectors, innovation inevitably requires international collaboration No country has all the expertise, tools, models, cohorts, etc. to

address the increasing challenge of discovery and development Knowledge creation is occurring all around the world and has to be

rapidly disseminated Research scientists seek expertise where they can find it – they are not

“place based”

No sector alone has the power to achieve these goals as well: public and private sectors also must increase

their collaboration!

9

The Issues New Opportunities for Collaboration How Massachusetts is Supporting New

Opportunities for Collaboration

10

Massachusetts: A Global Leader in Life Sciences

The Massachusetts Life Sciences Supercluster: The world’s leading innovation pipeline: The Milken Institute’s 2010

ratings rank Massachusetts #1 for technology innovation World-class academic and medical institutions leading the way in life

sciences research A talented workforce 95,000 workers in life sciences; 50% biopharma job growth in past decade All industry sectors -- biotechnology, pharmaceuticals, medical devices,

diagnostics and bioinformatics Government leadership, through our state’s 10-year, $1 billion Life

Sciences Initiative (enacted by the Massachusetts Legislature in June 2008)

11

The Massachusetts Life Sciences Center: Who We Are and What We Do

Mission: Serve as the “hub” of the Massachusetts life sciences

Supercluster Encourage innovation through investments in good science and

good business Strengthen and protect Massachusetts’ global leadership position

in the life sciences Accelerate the commercialization of promising treatments,

therapies and cures Create jobs and drive economic development

The Massachusetts Life Sciences Center develops and offers creative programs that fund innovation-driven economic development initiatives in the Massachusetts life sciences cluster, but also may have relevance for other “innovation” sectors.

12

Discovery Development Delivery

The MLSC Strategy:Reduce barriers, fill gaps and promote collaboration across the life

sciences innovation process

• Promote and fund convening and collaboration• Partner with and leverage private sector stakeholders

• Invest in early stage companies (pipeline and external innovation)• Support workforce development and training

• Build capacity, infrastructure and unique resources in Massachusetts

The MLSC Invests to Close Gaps Across the Innovation Life Cycle...

13

MLSCInvestments

…and Coalesce the Massachusetts Life Sciences “Cluster” into a “Ecosystem”

Life sciences innovation thrives in

Massachusetts because of the great

concentration of universities, research hospitals, educated

workers, entrepreneurs, mature companies and a

strong investment community.

In a high performing innovation clusters

these components work well individually and

together as an ecosystem

Top 5NIH fundedResearchHospitals

Top 5NIH funded

Research

Hospitals

430+Biotech

Companies

122Colleges &Universities

1st in Venture Capital & SBIR funds

per worker

1st in Education Level of

workforce

550Biopharma

Companies

122Colleges &

Universities

1st in Venture Capital & federal research

funds per worker

1st in Educational

Level of Workforce (US)

400Medtech

Companies

14

Life Sciences Initiative Investment Tools

• 10 years• $1 billionInvestment

$500

milli

on C

apita

l Fun

d$250 million

Tax Incentive Program

$250m Investment Fund (subject to appropriation)

15

Secretary of Housing and Economic Development Gregory Bialecki

Secretary of Administration and Finance Jay Gonzalez

President of the University of Massachusetts System Robert Caret, Ph.D.

A CEO of a Massachusetts-based life sciences corporation Abbie Celniker, Ph.D., CEO, Eleven Biotherapeutics

A researcher involved in the commercialization of biotechnology, pharmaceuticals or medical diagnostic products Lydia Villa-Komaroff, Director and CSO, Cytonome/ST

A physician licensed to practice medicine in the Commonwealth and affiliated with an academic medical center Edward Benz, M.D., President & CEO, Dana-Farber Cancer Institute

A person with financial expertise in the life sciences Joshua Boger, Ph.D., Founder & CEO (Retired), Vertex

The MLSC Board of Directors –Public and Private Sector Stakeholders Provide Governance

16

The MLSC Scientific Advisory Board FY ‘13CHAIR: Harvey Lodish, Ph.D.,

Whitehead Institute and Massachusetts Institute of Technology (MIT)

• James J. Collins, Ph.D., Boston University

• John M. Collins, Ph.D., Center for Integration of Medicine & Innovative Technology (CIMIT)

• Robert D’Amato, M.D., Ph.D., Center for Macular Degeneration Research , Harvard Medical School and Boston Children’s Hospital

• Rainer Fuchs, Ph.D., Harvard Medical School

• Glenn R. Gaudette, Ph.D., Worcester Polytechnic Institute (WPI)

• Judith Lieberman, Ph.D., Immune Disease Institute, Boston Children’s Hospital and Harvard Medical School

• Lita L. Nelsen, Massachusetts Institute of Technology (MIT)

• Barbara Osborne, Ph.D., UMass Amherst

• Guillermo Tearney, M.D., Ph.D., Harvard Medical School, Harvard-MIT Division of Health Sciences and Technology (HST) and Massachusetts General Hospital

• David Walt, Ph.D., Tufts University School of Medicine

• Philip Zamore, Ph.D., UMass Medical School

Academia

• Kevin Bitterman, Ph.D.,Polaris Venture Partners

• T. (Teo) Dagi, M.D., M.B.A.,HLM Venture Partners

• Jonathan Fleming, M.P.A.,Oxford Bioscience Partners

• Henry Kay, Boston Harbor Angels

• Carmichael Roberts, Ph.D., M.B.A.,

North Bridge Venture Partners• Lauren Silverman, Ph.D.,

Novartis Option Fund

Venture Capital

• James Barry, Ph.D., Arsenal Medical

• Dalia Cohen, Ph.D.,ALN Associates

• José-Carlos Gutiérrez-Ramos, Ph.D.,Pfizer

• Dale Larson,Draper Laboratory

• Alan Smith, Ph.D.,Formerly of Genzyme, a Sanofi Company

Industry

• Alison Taunton-Rigby, Ph.D. RiboNovix, Inc.

Entrepreneurs

17

Gaining Leverage: Public-Private PartnershipLife Sciences Center’s Impact: June ‘08 – May ‘13

Grants to Academic Organizations and Medical Centers

Grants for “Shovel Ready” Capital

Projects

Investments in Life Sciences Companies

Public Dollars Invested/ Committed

= $461 M

Matching Investments

Attracted = $1.2 B

3 X multiplier

Corporate Investors

NIH

Private Foundations

Institutes

Other Private Investors

Academic Institutions

18

Creating Opportunities for New Partnership Models Between Academia and Industry

Objective: encourage industry and Massachusetts academic institutions to explore new models of collaboration in discovery and development. Awards are made on a competitive basis. Key evaluation

criteria include: Impact of the focus area (product/technology) Novel aspects of the academic-industry collaboration Acceleration of “bench to bedside”

Focus areas to date have included therapeutics, devices, materials and tools

The Center has awarded 8 grants totaling $4.76 million Industry partners provide a (minimum) 1:1 match

19

Consortia in the Pre-Competitive Space Massachusetts is a center of excellence in the field of biomedical

neuroscience with world leaders representing all major fields of neurobiology and neurology.

The combination of basic neuroscience, translational, and clinical research distributed across more than a dozen world-renowned institutions amounts to what may be the highest density of neuroscience research in the world.

This provides a rich and fertile environment within which to advance our understanding and treatment of neurological disease.

The Massachusetts Life Sciences Neuroscience Consortium (MLSNC) is a pioneering new model that is designed to leverage this rich environment to: Accelerate pre-clinical research available to the pharmaceutical industry Introduce academic researchers to targeted research Facilitate new models of industry-academic partnership

20

MLSC Neuroscience ConsortiumObjective: Create a pioneering new model of collaboration designed to leverage Massachusetts’ rich neuroscience environment to:

Accelerate pre-clinical research available to the pharmaceutical industry Introduce academic researchers to targeted research Facilitate new models of industry-academic partnership

Massachusetts’ basic neuroscience, translational, and clinical research distributed across more than a dozen world-renowned institutions amounts to what may be the highest density of neuroscience research in the world.

Neuroscience Consortium Charter members:

Abbott Biogen-Idec EMD Serono Janssen Research (Johnson and

Johnson)

Merck Pfizer Sunovion (Dainippon

Sumitomo)

21

Consortia in the Pre-Competitive Space

Why is this Consortium Different? Proposed projects will be short-term and results-oriented.

Timelines/milestones, budgets and objectives will be clearly defined by the industry sponsors

Industry sponsors will identify common standards, e.g. levels of validation necessary for a project objective to be considered “complete.

Industry sponsors will work in collaboration with PIs and their teams; sponsors also will contribute tools, data and other resources to the project teams to expedite their work

Results are shared with all participants; sponsors and PIs will have access to the use of any tools developed by each project

Industry sponsors will determine their interest in validated targets as projects are completed. Co-development among consortium members is an option.

22

Consortia in the Pre-Competitive Space

Role of the Massachusetts Life Sciences Center The Massachusetts Life Sciences Center (MLSC) will use its convening

power to reduce barriers to collaboration and to expedite access to the research community

By acting as an intermediary, the MLSC also will enable industry to provide funding ‘at arms length’, thereby removin some of the administrative complications of direct corporate sponsorship of academic lab research

The MLSC will “staff” the Consortium so that all administrative costs are subsidized by the state and sponsors’ investments will be fully directed to funding projects

The Consortium received nearly 100 proposals in response to the initial solicitation and chose seven (7) projects to fund. For each project, a member(s) of the Consortium will work with the

PI and his/her team.

23

International Partnership Assistance Portal (IP-ap)Objective: Make it easier for international and Massachusetts companies to identify and pursue potential partnerships .

Massachusetts is open for collaboration: 24/7, 365 days a year!

Free, password-protected, cloud-based portal -- Create your user profile at https://partnering.masslifesciences.com

Open to MA-based life sciences companies and international life sciences companies

Companies describe their business and qualities they are seeking in a partner

Searchable database - MA companies can search MA and international companies, and international companies can search MA companies

24

International Collaborative Industry Program: Objectives and Approach

Our belief:

1 1 2Approach: Focus on collaborative life sciences industry

projects in late R&D or development Implement the collaboration through MLSC

and Partner agencies in other countries Execute through a competitive solicitation to

select promising project(s) between MA-based and non-U.S. based companies

Funding from MLSC to MA companies Funding from Partner agencies to the

international company partners Funding from each of the partner companies

Objectives: Promote and motivate

collaboration between life sciences companies in Massachusetts and other countries

Provide joint funding to subsidize the costs and accelerate the execution of these projects

25

International Collaborative Industry Program: Program Model

$$

Partner Agency

Min.100k Min. 100k

Min. 100k/project, Max. 500k Min. 100k /project

MLSC will match MA company

contribution

After a min. of $100k/project the rest is determined

by the agency

Joint R&D Project

Massachusetts Company

Non US-based Company

26

International Collaborative Industry Program:Program at a Glance

Collaboration between MA life sciences company and a life sciences company from another participating geography

Late R&D stage with a goal of commercialization Each company must have a well-defined role, set of responsibilities and

work plan The minimum grant level that Massachusetts applicants may be

awarded by MLSC is $100,000 and the maximum will be $500,000 MA company contribution must meet or exceed MLSC grant Other agencies specify the terms of their funding to local companies

and must provide minimum of $100,000 funding Program will involve a two-phased competitive RFP To receive funding, a final IP Agreement between the two companies

must be submitted

Objective: Jointly invest in international and Massachusetts R&D partnerships .

27

International Collaborative Industry Program (ICIP) Launch at BIO 2013

The announcement of ICIP included high-level representatives from our partnering regions including: Alsace Region in France Quebec Province in Canada Victoria State in Australia Wallonia Region in Belgium

28

Keeping in Touch

www.masslifesciences.com• News updates• Program Information• Application portal

Life Sciences Center Email List• 4,500 recipients• Weekly event listings • Sign up today!